These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 31289148)
21. Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease. Marizzoni M; Ferrari C; Macis A; Jovicich J; Albani D; Babiloni C; Cavaliere L; Didic M; Forloni G; Galluzzi S; Hoffmann KT; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Pizzini F; Rossini PM; Salvatore M; Schönknecht P; Soricelli A; Del Percio C; Hensch T; Hegerl U; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB; J Alzheimers Dis; 2019; 69(1):49-58. PubMed ID: 30958351 [TBL] [Abstract][Full Text] [Related]
22. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease. Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311 [TBL] [Abstract][Full Text] [Related]
23. Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. Chen K; Roontiva A; Thiyyagura P; Lee W; Liu X; Ayutyanont N; Protas H; Luo JL; Bauer R; Reschke C; Bandy D; Koeppe RA; Fleisher AS; Caselli RJ; Landau S; Jagust WJ; Weiner MW; Reiman EM; J Nucl Med; 2015 Apr; 56(4):560-6. PubMed ID: 25745091 [TBL] [Abstract][Full Text] [Related]
24. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment. Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L; Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868 [TBL] [Abstract][Full Text] [Related]
25. Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology. Insel PS; Mattsson N; Mackin RS; Schöll M; Nosheny RL; Tosun D; Donohue MC; Aisen PS; Jagust WJ; Weiner MW; Neurology; 2016 May; 86(20):1887-96. PubMed ID: 27164667 [TBL] [Abstract][Full Text] [Related]
35. Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease. Baker JE; Lim YY; Jaeger J; Ames D; Lautenschlager NT; Robertson J; Pietrzak RH; Snyder PJ; Villemagne VL; Rowe CC; Masters CL; Maruff P J Alzheimers Dis; 2018; 65(3):977-988. PubMed ID: 30103330 [TBL] [Abstract][Full Text] [Related]
36. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes. Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545 [TBL] [Abstract][Full Text] [Related]
37. Subthreshold Amyloid Predicts Tau Deposition in Aging. Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045 [TBL] [Abstract][Full Text] [Related]
38. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting. Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470 [TBL] [Abstract][Full Text] [Related]
39. Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia. Zhao Y; Tudorascu DL; Lopez OL; Cohen AD; Mathis CA; Aizenstein HJ; Price JC; Kuller LH; Kamboh MI; DeKosky ST; Klunk WE; Snitz BE JAMA Neurol; 2018 Jan; 75(1):88-96. PubMed ID: 29114732 [TBL] [Abstract][Full Text] [Related]
40. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study. Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]